Abstract
The resistance of tumors to classic taxanes (paclitaxel and docetaxel) presents problems in chemotherapy. Thus, new taxanes with higher antitumor activity in resistant tumors are synthesized. This study compared cytotoxicity and transport of paclitaxel and docetaxel with novel taxanes SB-T-1103, SB-T-1214, and SB-T-1216 in adriamycin-sensitive (MDA-MB-435) and -resistant (NCI/ADR-RES) human breast cancer cells. The cell lines examined differ in adriamycin transport, suggesting different expression of ABC membrane transporters. Reverse transcription-polymerase chain reaction revealed that NCI/ADR-RES cells expressed high levels of P-glycoprotein mRNA, which was absent in MDA-MB-435 cells, while the opposite was true for MRP2 mRNA. Both cell lines shared or differently expressed eight other ABC transporters and LRP. NCI/ADR-RES cells were 1,000-fold more resistant to paclitaxel and 600-fold more resistant to docetaxel in MTT assay than MDA-MB-435 cells, but almost equally sensitive to SB-T-1103, SB-T-1214, and SB-T-1216. This complied with the fact that NCI/ADR-RES cells absorbed almost 20-fold less [14C]paclitaxel, about 7-fold less docetaxel, and almost equal amounts of SB-T-1103, SB-T-1214, and SB-T-1216 as the MDA-MB-435 cells. Verapamil increased uptake of [14C]paclitaxel by NCI/ADR-RES cells 7-fold and decreased its efflux 2.5-fold; in contrast, it weakly influenced uptake and increased the efflux in MDA-MB-435 cells. SB-T-1103 and SB-T-1216 did not influence transport of paclitaxel, but SB-T-1214 decreased [14C]paclitaxel uptake in both cell lines indicating inhibition of uptake. This suggests that the novel taxanes are not inhibitors of P-glycoprotein. However, novel taxanes exert much higher activity on resistant tumor cells than classic taxanes and seem to be potential drugs for therapy in taxane-resistant tumors.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Cantiello HF (2001) Electrodiffusional ATP movement through CFTR and other ABC transporters. Pflügers Arch Eur J Physiol 443:S22–S27
Chomczynski P, Sacchi N (1987) Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156–159
Dean M, Rhetsky A, Allikmets R (2001) The human ATP-binding cassette (ABC) transporter superfamily. Genome Res 11:1156–1166
Ding S, Chamberlain M, McLaren A, Goh L, Duncan I, Wolf CR (2001) Cross-talk between signalling pathways and the multidrug resistant protein MDR-1. Br J Cancer 85:1175–1184
Eisenhauer EA, Vermorken JB (1998) The taxoids. Comparative clinical pharmacology and therapeutic potential. Drugs 55:5–30
Faneyte IF, Kristel PM, van de Vijver MJ (2001a) Determining MDR1/P-glycoprotein expression in breast cancer. Int J Cancer 93:114–122
Faneyte IF, Kristel PM, Vijver MJ (2001b) Multidrug resistance associated genes MRP1, MRP2 and MRP3 in primary and anthracycline exposed breast cancer. Anticancer Res 24:2931–2939
Ferguson RE, Jackson SM, Stanley AJ, Joyce AD, Harnden P, Morrison EE, Patel PM, Phillips RM, Selby PJ, Banks RE (2005) Intrinsic chemotherapy resistance to the tubulin-binding antimitotic agents in renal cell carcinoma. Int J Cancer 115:155–163
Ferlini C, Distefano M, Pignatelli F, Lin S, Riva A, Bombardelli E, Mancuso S, Ojima I, Scambia G (2000) Antitumour activity of novel taxanes act at the same time as cytotoxic agents and P-glycoprotein inhibitors. Br J Cancer 83:1762–1768
Ford JM, Hait WN (1990) Pharmacology of drugs that alter multidrug resistence in cancer. Pharmacol Rev 42:155–199
Garg MB, Ackland SP (2000) Simple and sensitive high-performance liquid chromatography. Method for determination of docetaxel in human plasma and urine. J Chromatogr B 748:383–388
Gottesman MM, Pastan I (1993) Modulation of multidrug resistance phenotype. Cell Pharmacol 1:S111–S112
Gut I, Danielova V, Holubova J, Soucek P, Kluckova H (2000) Cytotoxicity of cyclophosphamide, paclitaxel, and docetaxel for tumor cell lines in vitro: effects of concentration, time and cytochrome P450-catalyzed metabolism. Arch Toxicol 74:437–446
Huang Y, Anderle P, Bussey KJ, Barbacioru C, Shankavaram U, Dai Z, Reinhold WC, Papp A, Weinstein JN, Sadee W (2004) Membrane transporters and channels: role of the transportome in cancer chemosensitivity and chemoresistance. Cancer Res 64:4294–4301
Litman T, Zeuthen T, Skovsgaard T, Stein WD (1997) Competitive, non-competitive and cooperative interactions between substrates of P-glycoprotein as measured by its ATPase activity. Biochim Biophys Acta 1361:169–176
Litman T, Druley TE, Stein WD, Bates SE (2001) From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol Life Sci 58:931–959
Loo TW, Bartlett MC, Clarke DM (2003) Simultaneous binding of two different drugs in the binding pocket of the human multidrug resistance P-glycoprotein. J Biol Chem 278:39706–39710
Miller ML, Ojima I (2001) Chemistry and chemical biology of taxane anticancer agents. Chem Rec 1:195–211
Mosmann TJ (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55–63
Ojima I, Slater JC, Michaud E, Kuduk SD, Bounaud PY, Vrignaud P, Bissery MC, Veith JM, Pera P, Bernacki RJ (1996) Synthesis and structure-activity relationships of the second-generation antitumor taxoids: exceptional activity against drug-resistant cancer cells. J Med Chem 39:3889–3896
Parekh H, Simpkins H (1996) Species-specific differences in taxol transport and cytotoxicity against human and rodent tumor cells. Evidence for an alternate transport system. Biochem Pharmacol 51:301–311
Penson RT, Oliva E, Skates SJ, Glyptis T, Fuller AF Jr, Goodman A, Seiden MV (2004) Expression of multidrug resistance-1 protein inversely correlates with paclitaxel response and survival in ovarian cancer patients: a study in serial samples. Gynecol Oncol 93:98–106
Scheffer GL, Wijngaard PL, Flens MJ, Izquierdo MA, Slovak ML, Pinedo HM, Meijer CJ, Clevers HC, Scheper RJ (1995) The drug resistance-related protein LRP is the human major vault protein. Nat Med 1:578–582
Shepard RL, Winter MA, Hsaio SC, Pearce HL, Beck WT, Dantzig AH (1998) Effect of modulators on the ATPase activity and vanadate nucleotide trapping of human P-glycoprotein. Biochem Pharmacol 56:719–727
Taipalensuu J, Tornblom H, Lindberg G, Einarsson C, Sjoqvist F, Melhus H, Garberg P, Sjostrom B, Lundgren B, Artursson P (2001) Correlation of gene expression of ten drug efflux proteins of the ATP-binding cassette transporter family in normal human jejunum and in human intestinal epithelial Caco-2 cell monolayers. J Pharmacol Exp Ther 299:164–170
Vaclavikova R, Horsky S, Simek P, Gut I (2003) The paclitaxel metabolism in rat and human liver microsomes is inhibited by phenolic antioxidants. Naunyn-Schmiedebergs Arch Pharmacol 368:200–209
Van der Kolk DM, de Vries EG, van Putten WJ, Verdonck LF, Ossenkoppele GJ, Verhoef GE, Vellenga E (2000) P-glycoprotein and multidrug resistance protein activities in relation to treatment outcome in acute myeloid leukemia. Clin Cancer Res 6:3205–3214
Zhang JT (2001) The multi-structural feature of the multidrug resistance gene product P-glycoprotein: implications for its mechanism of action (hypothesis). Mol Membr Biol 18:145–152
Acknowledgements
This work was supported by grants IGA NL/7567-3 and GACR 305/04/0403 and grants from the National Institute of Health, USA, GM42978 and CA103314 (to I.O.)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ehrlichova, M., Vaclavikova, R., Ojima, I. et al. Transport and cytotoxicity of paclitaxel, docetaxel, and novel taxanes in human breast cancer cells. Naunyn Schmied Arch Pharmacol 372, 95–105 (2005). https://doi.org/10.1007/s00210-005-1080-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00210-005-1080-4